{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:09:07Z","timestamp":1784549347314,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019000","name":"Medical Affairs Bureau","doi-asserted-by":"publisher","award":["MND-MAB-C10-112041"],"award-info":[{"award-number":["MND-MAB-C10-112041"]}],"id":[{"id":"10.13039\/501100019000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019000","name":"Medical Affairs Bureau","doi-asserted-by":"publisher","award":["MND-MAB-D-114092"],"award-info":[{"award-number":["MND-MAB-D-114092"]}],"id":[{"id":"10.13039\/501100019000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["112-2314-B-016 -045 -MY3"],"award-info":[{"award-number":["112-2314-B-016 -045 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["112-2314-B-016 -047 -MY3"],"award-info":[{"award-number":["112-2314-B-016 -047 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-016-036"],"award-info":[{"award-number":["111-2314-B-016-036"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2026.111033","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:02:44Z","timestamp":1771722164000},"page":"111033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of denosumab treatment with survival and skeletal-related events in Asian men with mCRPC: A real-world observational study"],"prefix":"10.1016","volume":"44","author":[{"given":"Chien-Chang","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Lung","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tsung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ta","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2026.111033_bib0001","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"Jemal","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111033_bib0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111033_bib0003","first-page":"869","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111033_bib0004","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2004.08.016","article-title":"Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care","volume":"46","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111033_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2014.70","article-title":"Managing bone metastases and reducing skeletal related events in prostate cancer","volume":"11","author":"Gartrell","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.111033_bib0006","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"10.1016\/j.urolonc.2026.111033_bib0007","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111033_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111033_bib0009","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111033_bib0010","unstructured":"Network NCC. Prostate cancer (version 3.2024). Secondary Prostate cancer (version 3.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed October 12, 2024"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111033_bib0011","article-title":"Programmed cell death ligand 1 expression in circulating tumor cells as a predictor of treatment response in patients with urothelial carcinoma","volume":"10","author":"Chiang","year":"2021","journal-title":"Biology (Basel)"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111033_bib0012","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111033_bib0013","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.juro.2018.07.090","article-title":"Castration-resistant prostate cancer: AUA guideline amendment","volume":"200","author":"Lowrance","year":"2018","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111033_bib0014","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an endocrine society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111033_bib0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.acuro.2012.09.001","article-title":"Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK\/RANKL inhibition","volume":"37","author":"Gomez-Veiga","year":"2013","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.urolonc.2026.111033_bib0016","article-title":"Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.111033_bib0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fonc.2013.00329","article-title":"Effects of RANKL-targeted therapy in immunity and cancer","volume":"3","author":"Cheng","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.111033_bib0018","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejca.2021.06.005","article-title":"Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study","volume":"157","author":"Anton","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111033_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.16536","article-title":"Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy","volume":"4","author":"Francini","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111033_bib0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41391-020-00280-6","article-title":"Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases","volume":"24","author":"McGregor","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111033_bib0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41391-022-00573-y","article-title":"Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer","volume":"26","author":"Mitchell","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.111033_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116243","article-title":"Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe","volume":"154","author":"von Moos","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.urolonc.2026.111033_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.100212","article-title":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2019","journal-title":"J Bone Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111033_bib0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1590\/s1677-5538.ibju.2018.0798","article-title":"Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review","volume":"45","author":"Sasse","year":"2019","journal-title":"Int Braz J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111033_bib0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urolonc.2009.11.003","article-title":"Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer","volume":"29","author":"Payne","year":"2011","journal-title":"Urol Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.111033_bib0026","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111033_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12967-022-03861-2","article-title":"Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer","volume":"21","author":"Nuzzo","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111033_bib0028","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.clgc.2019.12.010","article-title":"METastasis reporting and data system for prostate cancer as a prognostic imaging marker in castration-resistant prostate cancer","volume":"18","author":"Yoshida","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"10.1016\/j.urolonc.2026.111033_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153802","article-title":"A systematic review of circulating tumor cells clinical application in prostate cancer diagnosis","volume":"14","author":"Enikeev","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111033_bib0030","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JCMA.0000000000000950","article-title":"Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: an experience before National Health Insurance reimbursement in Taiwan","volume":"86","author":"Yu","year":"2023","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111033_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13050705","article-title":"Biomarkers for prostate cancer bone metastasis detection and prediction","volume":"13","author":"Ying","year":"2023","journal-title":"J Pers Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:52:10Z","timestamp":1784548330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S107814392600044X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111033","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of denosumab treatment with survival and skeletal-related events in Asian men with mCRPC: A real-world observational study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111033"}}